Biotech bloodshed
Article Abstract:
There has been criticism of British Biotech chairman, Keith McCullagh, after the company's research director, Andrew Millar, was sacked, and the company was investigated by the Securities and Exchange Commission. Some stockholders are also concerned about a rapid drop in the company's stock price. Critics argue that Millar has been made a scapegoat. There is also concern about marimistat, the company's main anti-cancer drug which is scheduled to end trials by early 1999.
Publication Name: Investors Chronicle
Subject: Business
ISSN: 0261-3115
Year: 1998
User Contributions:
Comment about this article or add new information about this topic:
Rhein Biotech
Article Abstract:
Rhein Biotech has efficient production methods and licenses its technology. The company's potential is examined in detail.
Publication Name: Investors Chronicle
Subject: Business
ISSN: 0261-3115
Year: 2001
User Contributions:
Comment about this article or add new information about this topic:
GeneMedix plans generic biotech
Article Abstract:
GeneMedix is to become a generic producer of biotech proteins in countries where patents are not in force.
Publication Name: Investors Chronicle
Subject: Business
ISSN: 0261-3115
Year: 2000
User Contributions:
Comment about this article or add new information about this topic:
- Abstracts: Follow me. Shielding yourself. Don't bank on it
- Abstracts: Van Vechten & Co. Versaggi Biocomms
- Abstracts: Hope Beckham. The Dilenschneider Group
- Abstracts: Nashe Group. The Headline Group. Horn Group
- Abstracts: There's still life beyond the bubble. What's in a name? For geared, read feared